CommercialCoverageLow impact
Genetic Testing for Statin-Induced Myopathy (2.04.96)
Blue Shield of California·CA · Cardiology, Internal Medicine, Family Medicine +2 more·Genetic Testing
Effective date
Feb 1, 2026
We identified it
Nov 1, 2025
Summary
Blue Shield of California has updated its policy on genetic testing for statin-induced myopathy, maintaining that SLCO1B1 gene variant testing remains investigational and not covered. The policy is effective February 1, 2026, but billing teams should be aware of the current coverage status for any genetic testing requests related to statin therapy.
Action Required
Immediately: Billing team should verify that any genetic testing for SLCO1B1 variants related to statin-induced myopathy is not billed to Blue Shield of California as it remains investigational and non-covered. Inform providers that such testing should be discussed with patients as a potential out-of-pocket expense if clinically desired.